Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Ten-year experience with pharmacogenetic testing for DPYD in a national cancer center in Italy: Lessons learned on the path to implementation
Alessia Bignucolo, Elena De Mattia, Rossana Roncato, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 10

Showing 10 citing articles:

Pharmacogenetic Information on Drug Labels of the Italian Agency of Medicines (AIFA): Actionability and Comparison Across Other Regulatory Agencies
Antonino Moschella, Soumaya Mourou, Samantha Perfler, et al.
Clinical and Translational Science (2025) Vol. 18, Iss. 2
Open Access
Pharmacogenetic Testing in the Outpatient Setting in Switzerland: A Descriptive Study Using Swiss Claims Data
Nina L Wittwer, Christoph Meier, Carola A. Huber, et al.
Drug Safety (2025)
Open Access
Moving towards the implementation of pharmacogenetic testing in Quebec
Ling Li, Samuel Legeay, Ann-Lorie Gagnon, et al.
Frontiers in Genetics (2024) Vol. 14
Open Access | Times Cited: 3
Implementation of pre‐emptive testing of a pharmacogenomic panel in clinical practice: Where do we stand?
Elena Peruzzi, Rossana Roncato, Elena De Mattia, et al.
British Journal of Clinical Pharmacology (2023)
Open Access | Times Cited: 8
Implementing pharmacogenetic testing in fluoropyrimidine-treated cancer patients: DPYD genotyping to guide chemotherapy dosing in Greece
Georgia Ragia, Anthi Maslarinou, Natalia Atzemian, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 7
Advancing pharmacogenetic testing in a tertiary hospital: a retrospective analysis after 10 years of activity
Stefan Stewart, Jose Manuel Dodero-Anillo, Javier Guijarro-Eguinoa, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 4
DPYD genotype-guided dose personalisation for fluoropyrimidine-based chemotherapy prescribing in solid organ cancer patients in Australia: GeneScreen 5-FU study protocol
Cassandra White, Hannah R. Wardill, Christine Paul, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Clinical Benefits and Utility of Pretherapeutic DPYD and UGT1A1 Testing in Gastrointestinal Cancer
Rossana Roncato, Alessia Bignucolo, Elena Peruzzi, et al.
JAMA Network Open (2024) Vol. 7, Iss. 12, pp. e2449441-e2449441
Closed Access | Times Cited: 1
Why is There Still Debate About Recommending DPYD‐Testing Before Fluoropyrimidine Treatment?
Ingolf Cascorbi
Clinical Pharmacology & Therapeutics (2023) Vol. 114, Iss. 4, pp. 733-737
Open Access | Times Cited: 1
Pharmacogenetic DPYD allele variant frequencies: A comprehensive analysis across an ancestrally diverse Iranian population
Negar Sarhangi, Fatemeh Rouhollah, Negar Niknam, et al.
DARU Journal of Pharmaceutical Sciences (2024) Vol. 32, Iss. 2, pp. 715-727
Closed Access
Page 1

Scroll to top